Congressional Investigation into Alzheimer’s Drug Aduhelm Faults the F.D.A. and Biogen - The New York Times

The report said the F.D.A.’s approval process for Aduhelm was “rife with irregularities” and criticized Biogen for setting an “unjustifiably high price.”

saved by

• Emilie Wang